Artificial Blood Vessel Produced Using a 3D Bio-Printer

Artificial Blood Vessels Produced Using 3D Bio-Printer Through interdisciplinary R&D and development activities conducted by specialized engineers and scientists at Invamed RD Global's Production Campus, a leader in scientific and technological research in medical technologies, artificial blood vessels were produced in a laboratory environment. In a written statement from Invamed RD Global on the matter, it was reported that nearly 100 percent development of normal vessel elasticity was achieved through a specially developed three-dimensional printer and developed biotechnological infrastructure. The artificial blood vessels produced in Invamed & RD Global Laboratories are intended for use in cardiovascular and neurovascular prostheses. The production of artificial blood vessels from nanotechnological biopolymers enables patients to continue their lives without using anticoagulants due to these prostheses. In the statement, it was noted that the artificial blood vessels, developed with biopolymers very similar to normal vessel elasticity, were produced using high-level fluoropolymer technology, biopolymer, and three-dimensional bio-printers. This revolutionary step in medical technologies offers hope to patients awaiting organ transplants through three-dimensional printers and laser technology with complete integration properties to living tissue. Developed without the use of any biocompatible materials, the artificial blood vessels were reported to demonstrate properties identical to human tissue in terms of elasticity and tissue compatibility, as they contain no biocompatible materials.

It has been proven that patient-specific blood vessel production can be performed using 3D printers and laser scanning units

The statement included the following information: "In principle, both blood vessels are provided with very easy fusion properties with each other. It has been proven in a laboratory environment that this artificially produced synthetic blood vessel shows perfect compatibility with organic cells found in the human body. The method and production work with three-dimensional electrospinning, 3D printers, and laser scanning units has proven that patient-specific blood vessel production can be performed." Raşit Dinç, Chairman of Invamed & RD Global, stated in his remarks that if the artificial blood vessels that have successfully passed laboratory studies also prove successful through animal studies and subsequent clinical trials, bioprottheses will be made available to serve human health, and that very few surgical instruments exist in the global medical device market for this purpose. He noted that the use of three-dimensional electrospinning technology customized for each patient and production through nano-polymers, which would eliminate the need for the patient to use anticoagulants, is exciting, and the results of clinical studies must be awaited.